Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ: DMAA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Financial Services
- Industry
- Shell Companies
- CEO
- Roger Bendelac
- Employees
- 2
- Headquarters
- Fort Lauderdale, United States
- IPO year
- 2025
- Market cap
- $358.8M
- Website
- https://dmaacorp.com
Loading DMAA…
Loading profile data…Frequently asked questions about DMAA
What does Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) do?
Drugs Made In America Acquisition Corp. functions as a special purpose acquisition company, commonly known as a blank check company. Its core mission is to seek out and ultimately acquire one or more existing businesses or their assets. This acquisition strategy encompasses a variety of transactional methods, such as corporate mergers, capital s...
Where does DMAA trade?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) trades on the NASDAQ Global Select.
What sector is DMAA in?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) operates in the Financial Services sector, specifically in the Shell Companies industry.
Who is the CEO of Drugs Made In America Acquisition Corp. Ordinary Shares?
Roger Bendelac is the chief executive officer of Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA).
Where is Drugs Made In America Acquisition Corp. Ordinary Shares headquartered?
Drugs Made In America Acquisition Corp. Ordinary Shares is headquartered in United States.
Does DMAA pay a dividend?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DMAA go public?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) completed its initial public offering in 2025.